GlaxoSmithKline

GSK announces positive results of MATINEE trial, showing Nucala (mepolizumab) significantly reduces COPD exacerbations in type 2 inflammation patients.

Faruqi & Faruqi, LLP's James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Moderna between January 18, 2023, and June 25, 2024, to contact him directly to discuss their options. The firm is investigating potential claims against Moderna and reminds investors of the October 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges Moderna and its executives violated federal securities laws by making false and/or misleading statements regarding mRNA-1345's efficacy.

NOX inhibitors, including Calliditas Therapeutics' setanaxib, show potential in treating fibrotic diseases and cancers by reducing ROS levels, thereby allowing CD8+ T-cells to penetrate tumors and enhance immune response. Setanaxib has shown promising results in Phase II trials for squamous cell carcinoma of the head and neck, with plans for further trials in primary biliary cholangitis and Alport Syndrome.

The global pneumococcal vaccine market is projected to reach USD 12.19 billion by 2030, growing at a CAGR of 6.21% from 2024. Driven by increasing disease prevalence, government immunization programs, and new product launches, the market is dominated by the Pneumococcal Conjugate Vaccine segment, with Prevnar 13 leading in product category and the public sector in end-use. North America leads due to advanced healthcare and favorable regulations.

Bill Gates expresses optimism in the M72 tuberculosis vaccine's clinical trial, hoping for 70% efficacy. The trial, costing $500 million and done in collaboration with GSK and Wellcome Trust, aims to be the first new TB vaccine in over a century.

Adaptimmune, founded in 2008, has grown into a global biotech leader in TCR-T therapies for cancer. Despite challenges, it achieved FDA approval for afami-cel, marking a first in engineered cell therapy for solid tumors. Partnerships with GSK and others have been rocky, but recent deals and approvals signal potential growth.

GSK to present SWIFT-1 and SWIFT-2 phase III trial data for depemokimab, an ultra-long-acting biologic for severe asthma, at the 2024 ERS International Congress, aiming to achieve long-term clinical remission and advance respiratory medicine with 56 abstracts.

OCRA launches initiatives for Ovarian and Gynecologic Cancer Awareness Month, including $600,000 Health Equity Research Grants, a 'Find a Doctor' tool to connect patients with specialists, and an upcoming international grant program to foster global collaboration in cancer research, aiming to enhance access and equity in care.

GSK5764227, a B7-H3–targeted ADC, received FDA's Breakthrough Therapy Designation for ES-SCLC. ARTEMIS-001 study showed a 63.6% ORR and 81.8% DCR in SCLC patients, with manageable toxicity.

The FDA granted breakthrough therapy designation to GSK's GSK5764227 for treating relapsed or refractory ES-SCLC, supported by Phase I trial data. GSK plans global Phase I/II trials, aiming to accelerate development for this aggressive cancer with poor prognosis.